Once-monthly Abilify gains FDA nod

02/28/2013 | Bloomberg Businessweek

The FDA has granted Otsuka Holdings and H. Lundbeck approval for Abilify Maintena, a once-a-month injection for patients with schizophrenia. The drug was associated with significant delays in relapse compared with placebo, the company said.

View Full Article in:

Bloomberg Businessweek

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA